IN2013MN00601A - - Google Patents

Download PDF

Info

Publication number: IN2013MN00601A
Authority: IN; India
Prior art keywords: nox proteins; delivery; nox; type; gas
Prior art date: 2006-05-22

Application number

Other languages

English (en)

Inventor

Stephen P I Cary

Elizabeth M Boon

Emily Weinert

Jonathan A Winger

Michael A Marletta

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-22

Filing date

2007-05-21

Publication date

2015-06-12

2007-05-21 Application filed by Univ California filed Critical Univ California

2015-06-12 Publication of IN2013MN00601A publication Critical patent/IN2013MN00601A/en

Links

102000004169 proteins and genes Human genes 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
239000008280 blood Substances 0.000 abstract 2
210000004369 blood Anatomy 0.000 abstract 2
230000009286 beneficial effect Effects 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000035772 mutation Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
- C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/102499—Blood gas standard or control

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Toxicology (AREA)
Cardiology (AREA)
Insects & Arthropods (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IN601MUN2013 2006-05-22 2007-05-21 IN2013MN00601A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92150506P	2006-05-22	2006-05-22
PCT/US2007/012184 WO2007139791A2 (en)	2006-05-22	2007-05-21	Compositions and methods for the delivery of oxygen

Publications (1)

Publication Number	Publication Date
IN2013MN00601A true IN2013MN00601A (pt)	2015-06-12

Family

ID=38779160

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IN600MUN2013 IN2013MN00600A (pt)	2006-05-22	2007-05-21
IN601MUN2013 IN2013MN00601A (pt)	2006-05-22	2007-05-21

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
IN600MUN2013 IN2013MN00600A (pt)	2006-05-22	2007-05-21

Country Status (12)

Country	Link
US (7)	US8404631B2 (pt)
EP (7)	EP2032156B1 (pt)
JP (5)	JP5698906B2 (pt)
CN (5)	CN101495506B (pt)
AU (2)	AU2007268028B2 (pt)
BR (2)	BRPI0711901A2 (pt)
CA (2)	CA2653101C (pt)
DK (4)	DK2463294T3 (pt)
ES (4)	ES2611157T3 (pt)
IN (2)	IN2013MN00600A (pt)
NZ (4)	NZ594457A (pt)
WO (2)	WO2007139767A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ594457A (en) *	2006-05-22	2013-06-28	Univ California	Compositions and methods for the delivery of oxygen
US20110243849A1 (en) *	2010-04-02	2011-10-06	Marletta Michael A	Heme-binding photoactive polypeptides and methods of use thereof
ES2886531T3 (es)	2013-01-07	2021-12-20	Omniox Inc	Formas poliméricas de proteínas H-NOX
CA2979974A1 (en) *	2015-03-17	2016-09-22	Omniox, Inc.	Modulation of tumor immunity by protein-mediated o2 delivery
CA3014651A1 (en) *	2016-02-16	2017-08-24	Omniox, Inc.	Modulation of hypoxia associated with stroke
JP6467073B2 (ja) *	2018-01-04	2019-02-06	オムニオクス，インコーポレイテッド	Ｈ−ｎｏｘタンパク質の重合体形態
EP3836911A1 (en)	2018-08-15	2021-06-23	Omniox, Inc.	H-nox proteins for treating cardiovascular and pulmonary conditions
CN119264211A (zh)	2018-08-27	2025-01-07	瑞泽恩制药公司	拉曼光谱在下游纯化中的应用
WO2020263830A1 (en)	2019-06-25	2020-12-30	Gilead Sciences, Inc.	Flt3l-fc fusion proteins and methods of use
ES2973832T3 (es)	2019-10-18	2024-06-24	Forty Seven Inc	Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
JP2022552748A (ja)	2019-10-31	2022-12-19	フォーティセブン，インコーポレイテッド	抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
TWI778443B (zh)	2019-11-12	2022-09-21	美商基利科學股份有限公司	Mcl1抑制劑
IL294032A (en)	2019-12-24	2022-08-01	Carna Biosciences Inc	Compounds that regulate diacylglycerol kinase
TWI890283B (zh)	2020-02-14	2025-07-11	美商基利科學股份有限公司	結合ccr8之抗體及融合蛋白及其用途
IL297327B2 (en)	2020-05-01	2026-01-01	Gilead Sciences Inc	4,2-dioxopyrimidine compounds CD73 inhibitors
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en)	2021-05-18	2022-11-24	Gilead Sciences, Inc.	Methods of using flt3l-fc fusion proteins
AU2022299051B2 (en)	2021-06-23	2025-03-13	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
JP7651018B2 (ja)	2021-06-23	2025-03-25	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es)	2021-06-23	2024-01-15	Gilead Sciences Inc	Compuestos moduladores de diacilglicerol quinasa.
JP7686091B2 (ja)	2021-06-23	2025-05-30	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
AU2022375782B2 (en)	2021-10-28	2026-02-26	Gilead Sciences, Inc.	Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja)	2021-10-29	2025-12-17	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｄ７３化合物
KR20240123836A (ko)	2021-12-22	2024-08-14	길리애드 사이언시즈, 인코포레이티드	이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12122764B2 (en)	2021-12-22	2024-10-22	Gilead Sciences, Inc.	IKAROS zinc finger family degraders and uses thereof
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
WO2023178181A1 (en)	2022-03-17	2023-09-21	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
KR20240165995A (ko)	2022-03-24	2024-11-25	길리애드 사이언시즈, 인코포레이티드	Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh)	2022-04-05	2025-03-11	美商基利科學股份有限公司	用於治療結腸直腸癌之組合療法
CR20240451A (es)	2022-04-21	2024-12-04	Gilead Sciences Inc	Compuestos de modulación de kras g12d
KR20250028371A (ko)	2022-07-01	2025-02-28	길리애드 사이언시즈, 인코포레이티드	Cd73 화합물
WO2024064668A1 (en)	2022-09-21	2024-03-28	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AU2023409398A1 (en)	2022-12-22	2025-06-05	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
AU2024252725A1 (en)	2023-04-11	2025-11-06	Gilead Sciences, Inc.	Kras modulating compounds
CR20250446A (es)	2023-04-21	2025-12-02	Gilead Sciences Inc	Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en)	2023-06-30	2026-01-08	Gilead Sciences, Inc.	Kras modulating compounds
CN121620513A (zh)	2023-07-26	2026-03-06	吉利德科学公司	Parp7抑制剂
KR20260046403A (ko)	2023-07-26	2026-04-07	길리애드 사이언시즈, 인코포레이티드	Parp7 저해제
US20250101042A1 (en)	2023-09-08	2025-03-27	Gilead Sciences, Inc.	Kras g12d modulating compounds
US20250109147A1 (en)	2023-09-08	2025-04-03	Gilead Sciences, Inc.	Kras g12d modulating compounds
US20250154172A1 (en)	2023-11-03	2025-05-15	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2025137640A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
WO2025245003A1 (en)	2024-05-21	2025-11-27	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20260098049A1 (en)	2024-08-12	2026-04-09	Gilead Sciences, Inc.	Kras modulating compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873192A (en) *	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US6022849A (en)	1987-05-16	2000-02-08	Baxter Biotech Technology Saarl	Mutant recombinant hemoglobins containing heme pocket mutations
US5731454A (en)	1990-02-12	1998-03-24	Virginia Commonwealth University	Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
WO1995027040A1 (en)	1994-04-01	1995-10-12	Unisyn Technologies, Inc.	Culture media additives for hollow fiber bioreactors
ATE302019T1 (de)	1997-02-28	2005-09-15	Univ California	Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
CA2299049C (en) *	1997-05-02	2008-07-15	Baxter Biotech Technology S.A.R.L.	Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
DE19837015C2 (de) *	1998-08-14	2003-03-20	Vasopharm Biotech Gmbh	Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6773613B1 (en) *	1998-10-15	2004-08-10	Sangart, Inc.	Method for production of stroma-free hemoglobin
EP1250155B1 (en) *	1999-12-22	2008-04-16	The Scripps Research Institute	Angiogenesis and vascular permeability modulators and inhibitors
WO2002002757A2 (en)	2000-06-29	2002-01-10	Incyte Genomics, Inc.	Adenylyl and guanylyl cyclases
US20030096240A1 (en) *	2000-09-19	2003-05-22	Ferid Murad	Genomic organization of mouse and human sGC
US6780849B2 (en) *	2000-12-21	2004-08-24	Scimed Life Systems, Inc.	Lipid-based nitric oxide donors
US20030153491A1 (en)	2002-01-11	2003-08-14	Winslow Robert M.	Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20060130158A1 (en) *	2002-08-30	2006-06-15	Turner Andrew J	Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
CN1660100A (zh) *	2002-12-09	2005-08-31	上海倍艺医药科技有限公司	一种治疗糖尿病及其并发症的药物
NZ594457A (en)	2006-05-22	2013-06-28	Univ California	Compositions and methods for the delivery of oxygen

2007
- 2007-05-21 NZ NZ594457A patent/NZ594457A/xx unknown
- 2007-05-21 EP EP07795174A patent/EP2032156B1/en active Active
- 2007-05-21 AU AU2007268028A patent/AU2007268028B2/en active Active
- 2007-05-21 CA CA2653101A patent/CA2653101C/en active Active
- 2007-05-21 JP JP2009512107A patent/JP5698906B2/ja active Active
- 2007-05-21 EP EP11189808A patent/EP2463295A1/en not_active Withdrawn
- 2007-05-21 NZ NZ594456A patent/NZ594456A/xx unknown
- 2007-05-21 CA CA2653080A patent/CA2653080C/en active Active
- 2007-05-21 EP EP07795153.1A patent/EP2040740B1/en active Active
- 2007-05-21 DK DK11189807.8T patent/DK2463294T3/en active
- 2007-05-21 ES ES11189814.4T patent/ES2611157T3/es active Active
- 2007-05-21 ES ES11189807.8T patent/ES2610653T3/es active Active
- 2007-05-21 EP EP11189814.4A patent/EP2463297B1/en active Active
- 2007-05-21 JP JP2009512098A patent/JP5698905B2/ja active Active
- 2007-05-21 EP EP11189818A patent/EP2474554A3/en not_active Withdrawn
- 2007-05-21 IN IN600MUN2013 patent/IN2013MN00600A/en unknown
- 2007-05-21 DK DK07795153.1T patent/DK2040740T3/en active
- 2007-05-21 BR BRPI0711901-1A patent/BRPI0711901A2/pt not_active Application Discontinuation
- 2007-05-21 CN CN200780027798.7A patent/CN101495506B/zh active Active
- 2007-05-21 EP EP11189812A patent/EP2463296A1/en not_active Withdrawn
- 2007-05-21 DK DK11189814.4T patent/DK2463297T3/en active
- 2007-05-21 NZ NZ573004A patent/NZ573004A/en unknown
- 2007-05-21 US US12/302,002 patent/US8404631B2/en active Active
- 2007-05-21 AU AU2007268052A patent/AU2007268052B2/en active Active
- 2007-05-21 CN CN201410766335.4A patent/CN104689300B/zh active Active
- 2007-05-21 WO PCT/US2007/012133 patent/WO2007139767A2/en not_active Ceased
- 2007-05-21 NZ NZ573003A patent/NZ573003A/en unknown
- 2007-05-21 BR BRPI0711767A patent/BRPI0711767B8/pt active IP Right Grant
- 2007-05-21 EP EP11189807.8A patent/EP2463294B1/en active Active
- 2007-05-21 US US12/302,004 patent/US8404632B2/en active Active
- 2007-05-21 CN CN201810357346.5A patent/CN108273040A/zh active Pending
- 2007-05-21 DK DK07795174.7T patent/DK2032156T3/da active
- 2007-05-21 IN IN601MUN2013 patent/IN2013MN00601A/en unknown
- 2007-05-21 WO PCT/US2007/012184 patent/WO2007139791A2/en not_active Ceased
- 2007-05-21 ES ES07795153.1T patent/ES2525226T3/es active Active
- 2007-05-21 CN CN201610487363.1A patent/CN106075388B/zh active Active
- 2007-05-21 ES ES07795174T patent/ES2399662T3/es active Active
- 2007-05-21 CN CN200780027797.2A patent/CN101495134B/zh active Active
2013
- 2013-02-20 US US13/772,281 patent/US20130288970A1/en not_active Abandoned
- 2013-02-20 US US13/772,283 patent/US20130289252A1/en not_active Abandoned
2014
- 2014-09-04 JP JP2014180140A patent/JP6118772B2/ja active Active
- 2014-09-04 JP JP2014180132A patent/JP6118296B2/ja active Active
- 2014-09-17 US US14/489,395 patent/US9493526B2/en active Active
- 2014-09-18 US US14/490,597 patent/US9493527B2/en active Active
2016
- 2016-10-12 US US15/292,012 patent/US10202428B2/en active Active
2017
- 2017-03-27 JP JP2017061455A patent/JP6458070B2/ja active Active

Also Published As

Publication number	Publication date
CN101495506B (zh)	2016-08-10
IN2013MN00600A (pt)	2015-06-12
EP2463297A1 (en)	2012-06-13
WO2007139791A2 (en)	2007-12-06
NZ573003A (en)	2012-06-29
JP6118296B2 (ja)	2017-04-19
US20100285104A1 (en)	2010-11-11
CN108273040A (zh)	2018-07-13
BRPI0711767A2 (pt)	2012-01-10
JP5698905B2 (ja)	2015-04-08
NZ594456A (en)	2013-06-28
NZ594457A (en)	2013-06-28
WO2007139791A3 (en)	2008-05-02
EP2040740A4 (en)	2009-10-21
WO2007139767A3 (en)	2008-02-07
JP5698906B2 (ja)	2015-04-08
EP2474554A2 (en)	2012-07-11
JP2015007108A (ja)	2015-01-15
CA2653101A1 (en)	2007-12-06
ES2611157T3 (es)	2017-05-05
JP2017137337A (ja)	2017-08-10
US9493527B2 (en)	2016-11-15
EP2032156B1 (en)	2012-11-21
WO2007139767A2 (en)	2007-12-06
BRPI0711767B8 (pt)	2021-05-25
CN101495506A (zh)	2009-07-29
EP2463295A1 (en)	2012-06-13
EP2463294A1 (en)	2012-06-13
EP2032156A2 (en)	2009-03-11
JP2009538134A (ja)	2009-11-05
CN104689300B (zh)	2018-06-05
BRPI0711901A2 (pt)	2012-03-06
EP2463294B1 (en)	2016-10-19
CN106075388A (zh)	2016-11-09
JP6118772B2 (ja)	2017-04-19
ES2399662T3 (es)	2013-04-02
CN106075388B (zh)	2021-06-29
CA2653101C (en)	2016-12-13
EP2474554A3 (en)	2012-10-03
CN101495134B (zh)	2016-08-03
DK2463297T3 (en)	2017-01-09
CN104689300A (zh)	2015-06-10
JP6458070B2 (ja)	2019-01-23
JP2014224156A (ja)	2014-12-04
HK1129688A1 (en)	2009-12-04
EP2032156A4 (en)	2009-11-11
ES2610653T3 (es)	2017-04-28
US20170267732A1 (en)	2017-09-21
BRPI0711767B1 (pt)	2018-05-15
US20130289252A1 (en)	2013-10-31
EP2040740B1 (en)	2014-09-03
DK2032156T3 (da)	2013-02-18
DK2463294T3 (en)	2017-01-16
US8404632B2 (en)	2013-03-26
US20150266931A1 (en)	2015-09-24
CA2653080A1 (en)	2007-12-06
US20100266673A1 (en)	2010-10-21
EP2463297B1 (en)	2016-10-19
CN101495134A (zh)	2009-07-29
CA2653080C (en)	2019-02-12
AU2007268028A1 (en)	2007-12-06
US20130288970A1 (en)	2013-10-31
AU2007268028B2 (en)	2013-03-14
US9493526B2 (en)	2016-11-15
EP2040740A2 (en)	2009-04-01
US10202428B2 (en)	2019-02-12
JP2009538133A (ja)	2009-11-05
ES2525226T3 (es)	2014-12-19
EP2463296A1 (en)	2012-06-13
AU2007268052A1 (en)	2007-12-06
US20150376250A1 (en)	2015-12-31
US8404631B2 (en)	2013-03-26
AU2007268052B2 (en)	2013-07-04
NZ573004A (en)	2012-06-29
DK2040740T3 (en)	2014-12-01

Publication	Publication Date	Title
IN2013MN00601A (pt)	2015-06-12
PH12019500644A1 (en)	2020-10-12	Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EA201200519A1 (ru)	2012-09-28	Стабилизированные жидкие и лиофилизированные композиции adamts13
TN2010000128A1 (en)	2011-09-26	Antibodies specific for the protofibril form of beta-amyloid protein
MX2009006760A (es)	2009-08-20	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
EA201000735A1 (ru)	2010-12-30	Композиции многотипных пептидов hpv и способы лечения или предотвращения папилломавирусной инфекции у человека
PH12017502286A1 (en)	2019-11-11	Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
EP3219725A3 (en)	2017-11-22	Dkk1 antibodies and methods of use
MX358836B (es)	2018-09-05	Proteinas f del vrs modificadas y metodos de uso de las mismas.
IL190796A0 (en)	2008-11-03	Compositions and their uses for gene therapy of bone conditions
MX2009004862A (es)	2009-07-17	Estabilizacion de vacunas por liofilizacion.
MX2009008928A (es)	2010-01-27	Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
TW201713640A (en)	2017-04-16	Bruton's tyrosine kinase inhibitors
NO20074446L (no)	2007-11-01	DR5-antistoffer og anvendelser derav
UA108198C2 (uk)	2015-04-10	Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
GEP20146181B (en)	2014-10-27	Anti cxcr4 antibodies for treatment of hiv
WO2010021874A3 (en)	2016-03-24	Engineered anti-il-13 antibodies, compositions, methods and uses
UA102251C2 (ru)	2013-06-25	Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EP2576578A4 (en)	2013-12-04	POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MX2009006345A (es)	2009-06-23	Compuestos utiles como inhibidores de proteina cinasa.
DE602007010764D1 (en)	2011-01-05	Benzamidglucokinaseaktivatoren
ATE510907T1 (de)	2011-06-15	Adenovirus mit mutationen in der domäne des e3- 19k-proteins zur retention im endoplasmatischen retikulum und verwendung in der krebsbehandlung
TN2009000194A1 (en)	2010-10-18	Novel antiproliferation antibodies
EP2274437A4 (en)	2011-11-16	COMPOSITIONS AND METHODS FOR DETECTING EGFR MUTATIONS IN CANCER
MX2011013032A (es)	2012-02-08	Inhibidores de fosfatidilinositol 3-cinasa.